Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilengitide in Metastatic Melanoma
NCT00082875Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2004
- Primary completion
- Jul 2006
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cilengitide in melanoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival Rate at 8 weeks. Started Mar 2004; status: terminated.
02
Drugs
cilengitide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00082875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082875.